245 related articles for article (PubMed ID: 12713619)
41. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas.
Broll R; Stark A; Windhövel U; Best R; Strik MW; Schimmelpenning H; Schwandner O; Kujath P; Bruch HP; Duchrow M
Eur J Cancer; 1999 Jul; 35(7):1083-8. PubMed ID: 10533452
[TBL] [Abstract][Full Text] [Related]
42. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
43. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
44. Inflammatory myofibroblastic tumor with predominant anaplastic lymphoma kinase-positive cells lacking a myofibroblastic phenotype.
Hisaoka M; Shimajiri S; Matsuki Y; Meis-Kindblom JM; Kindblom LG; Li XQ; Wang J; Hashimoto H
Pathol Int; 2003 Jun; 53(6):376-81. PubMed ID: 12787312
[TBL] [Abstract][Full Text] [Related]
45. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
Boltze C; Schneider-Stock R; Jäger V; Roessner A
Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050
[TBL] [Abstract][Full Text] [Related]
46. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
[TBL] [Abstract][Full Text] [Related]
47. Accumulation of MDM2 in pleomorphic xanthoastrocytomas.
Matsumoto K; Suzuki SO; Fukui M; Iwaki T
Pathol Int; 2004 Jun; 54(6):387-91. PubMed ID: 15144396
[TBL] [Abstract][Full Text] [Related]
48. Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: a preliminary clinicopathological study of nine cases and review of the literature.
Freeman A; Geddes N; Munson P; Joseph J; Ramani P; Sandison A; Fisher C; Parkinson MC
Mod Pathol; 2004 Jul; 17(7):765-71. PubMed ID: 15105807
[TBL] [Abstract][Full Text] [Related]
49. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
50. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
McCann AH; Kirley A; Carney DN; Corbally N; Magee HM; Keating G; Dervan PA
Br J Cancer; 1995 May; 71(5):981-5. PubMed ID: 7734324
[TBL] [Abstract][Full Text] [Related]
51. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator.
Watanabe T; Oda Y; Tamiya S; Kinukawa N; Masuda K; Tsuneyoshi M
Histopathology; 2001 Aug; 39(2):187-97. PubMed ID: 11493336
[TBL] [Abstract][Full Text] [Related]
52. Pancreatic malignant fibrous histiocytoma, inflammatory myofibroblastic tumor, and inflammatory pseudotumor related to autoimmune pancreatitis: characterization and differential diagnosis.
Mizukami H; Yajima N; Wada R; Matsumoto K; Kojima M; Klöppel G; Yagihashi S
Virchows Arch; 2006 May; 448(5):552-60. PubMed ID: 16538442
[TBL] [Abstract][Full Text] [Related]
53. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
[TBL] [Abstract][Full Text] [Related]
54. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
[TBL] [Abstract][Full Text] [Related]
55. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
56. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.
Møller MB; Ino Y; Gerdes AM; Skjødt K; Louis DN; Pedersen NT
Leukemia; 1999 Mar; 13(3):453-9. PubMed ID: 10086736
[TBL] [Abstract][Full Text] [Related]
57. Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma.
Li JJ; Huang YQ; Cockerell CJ; Zhang WG; Nicolaides A; Friedman-Kien AE
Am J Dermatopathol; 1997 Aug; 19(4):373-8. PubMed ID: 9261472
[TBL] [Abstract][Full Text] [Related]
58. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas.
Nasir L; Rutteman GR; Reid SW; Schulze C; Argyle DJ
Cancer Lett; 2001 Dec; 174(1):83-9. PubMed ID: 11675155
[TBL] [Abstract][Full Text] [Related]
59. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A
Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960
[TBL] [Abstract][Full Text] [Related]
60. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
